Announcements
- BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA Meeting
- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024
- BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at ESC-HF, Including That Acoramidis Treatment Significantly Reduced All-Cause Mortality in a Pre-specified Sensitivity Analysis of the Entire Study Population
- BridgeBio Pharma Reports First Quarter 2024 Financial Results and Business Update
- BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipeline
- BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
- BridgeBio Pharma Announces Pricing of Public Offering of Common Stock
- BridgeBio Pharma Announces Proposed Public Offering of Common Stock
- BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM
More ▼
Key statistics
As of last trade, BridgeBio Pharma Inc (2CL:FRA) traded at 25.71, 111.00% above the 52 week low of 12.19 set on May 24, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 25.46 |
---|---|
High | 25.71 |
Low | 25.46 |
Bid | 25.53 |
Offer | 26.05 |
Previous close | 25.58 |
Average volume | 707.56 |
---|---|
Shares outstanding | 187.13m |
Free float | 144.85m |
P/E (TTM) | -- |
Market cap | 5.19bn USD |
EPS (TTM) | -3.23 USD |
Data delayed at least 15 minutes, as of May 24 2024 14:45 BST.
More ▼